Olumiant®

(baricitinib)

2 mg and 4 mg, film-coated tablets

Summary of Risk Management Plan (RMP)
Summary of the risk management plan (RMP) for Olumiant (baricitinib)
The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimize them.
The RMP summary of Olumiant is a concise document and does not claim to be exhaustive. As the RMP is an international document, the summary might differ from the „Arzneimittelinformation / Information sur le médicament“ approved and published in Switzerland, e.g. by mentioning risks occurring in populations or indications not included in the Swiss authorization. Please note that the reference document which is valid and relevant for the effective and safe use of Olumiant in Switzerland is the „Arzneimittelinformation/ Information sur le médicament“ (see www.swissmedicinfo.ch) approved and authorized by Swissmedic.
Eli Lilly is fully responsible for the accuracy and correctness of the content of this published summary RMP of Olumiant.

I. The Medicine and What It Is Used For
Olumiant is authorised for moderate to severe RA (see SmPC for the full indication). It contains baricitinib as the active substance and it is given by mouth.
Further information about the evaluation of Olumiant’s benefits can be found in Olumiant’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks
Important risks of Olumiant, together with measures to minimise such risks and the proposed studies for learning more about Olumiant’s risks, are outlined below.
Measures to minimise the risks identified for medicinal products can be:
Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and HCPs.
Together, these measures constitute routine risk minimisation measures.
In the case of Olumiant, these measures are supplemented with additional risk minimisation measures mentioned under relevant important risks, below.
In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report assessment so that immediate action can be taken as necessary. These measures constitute routine PV activities.
If important information that may affect the safe use of Olumiant is not yet available, it is listed under ‘missing information’ below.

II.A. List of Important Risks and Missing Information
Important risks of Olumiant are risks that need special risk management activities to further investigate or minimise the risk so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Olumiant. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g., on the long-term use of the medicine).

<table>
<thead>
<tr>
<th>List of Important Risks and Missing Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Important identified risks</td>
</tr>
<tr>
<td>Herpes zoster</td>
</tr>
</tbody>
</table>
List of Important Risks and Missing Information

<table>
<thead>
<tr>
<th>Important potential risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Malignancies (including lymphoma and typically virus-induced malignancies such as cervical and many oropharyngeal cancers)</td>
</tr>
<tr>
<td>Serious and opportunistic infections (including tuberculosis, <em>Candida</em> infections, PML)</td>
</tr>
<tr>
<td>Myelosuppression (agranulocytosis)</td>
</tr>
<tr>
<td>Myopathy including rhabdomyolysis</td>
</tr>
<tr>
<td>Potential for drug-induced liver injury</td>
</tr>
<tr>
<td>Gastrointestinal perforation</td>
</tr>
<tr>
<td>MACE as an outcome of hyperlipidaemia</td>
</tr>
<tr>
<td>Foetal malformation following exposure in utero</td>
</tr>
<tr>
<td>VTE</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Missing information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term safety</td>
</tr>
<tr>
<td>Use in very elderly (≥75 years)</td>
</tr>
<tr>
<td>Use in patients with evidence of hepatitis B or hepatitis C infection</td>
</tr>
<tr>
<td>Use in patients with a history of or current lymphoproliferative disease</td>
</tr>
<tr>
<td>Use in patients with active or recent primary or recurrent malignant disease</td>
</tr>
<tr>
<td>Use in paediatric patients</td>
</tr>
</tbody>
</table>

Abbreviations: MACE = major adverse cardiovascular event; PML = progressive multifocal leukoencephalopathy; VTE = venous thromboembolic event.

II.B. Summary of Important Risks

<table>
<thead>
<tr>
<th>Important identified risk: Herpes Zoster</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence for linking the risk to the medicine</td>
</tr>
<tr>
<td>In the CT development programme, observed cases of herpes zoster have been predominantly classified as nonserious (89%). The majority (95%) of the reported cases were classified by the investigator as mild to moderate in severity. A similar profile has also been reported from everyday clinical practice since baricitinib was first marketed in the EU on 13 February 2017. As would be expected in a medical condition that is usually treated by specialists, the majority of herpes zoster cases have been readily diagnosed, managed, and typically resolved without long-term sequelae. More clinically important manifestations of herpes zoster have been reported very rarely with cases in which the rash spreads beyond the primary or adjacent dermatomes (multidermatomal herpes zoster) being reported in 8.5% of patients in CTs; herpes zoster was associated with motor nerve involvement in 0.1% of cases. A common complication of this infection, irrespective of the cause, is post-herpetic neuralgia. This has been reported in a low proportion of patients who developed herpes (5%).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk factors and risk groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>A notable proportion of the cases of herpes zoster (26.4%) reported in the baricitinib clinical trials, originated from patients in Japan. where the reporting rate was higher than that from any other countries. Heavily pretreated elderly patients appear to be at higher risk of herpes zoster.</td>
</tr>
</tbody>
</table>
### Risk minimisation measures

**[Routine risk minimisation measures:]**

- **SmPC Section 4.8**
  - **SmPC Section 4.4** recommends that if an infection develops, the patient should be monitored carefully, and Olumiant should be temporarily interrupted and not be resumed until the infection resolves. There is a further recommendation that, prior to starting treatment, all patients be brought up to date with all immunisations.
- **PIL Sections 2 and 4**
  - **PL Section 2** advises that the patient should tell their doctor if they develop signs of shingles.

**[Additional risk minimisation measures:]**

- Healthcare Professional Educational Material
- Patient Alert Card

### Additional PV activities

- **Additional PV activities:**
  - Observational post-marketing safety studies to monitor the incidence of herpes zoster in patients exposed to baricitinib
  - National RA registries, such as Corrona
  - EU registries
  - An observational database study
  - Nordic healthcare study
  - See Section II.C of this summary for an overview of the post-authorisation development plan.

### Important potential risk: Malignancies (including lymphoma and typically virus-induced malignancies such as cervical and many oropharyngeal cancers)

#### Evidence for linking the risk to the medicine

The association between immunomodulatory products like baricitinib and malignancy is largely theoretical and based on a putative effect on the immune system and the capacity for cancer immunosurveillance (a process by which the body's immune system recognises transformed cells in order to inhibit the growth of neoplastic tissue). In contrast, it is also suspected that the chronic inflammation present in RA and other autoimmune conditions, rather than its treatment, may underlie the increased incidence of lymphoma observed in these patients compared to the general population, through its continuous stimulation of B cells (Baecklund et al. 2006; Beyaert et al. 2013) or through induction of Epstein Barr virus replication (Hollander et al. 2015). The most commonly reported malignancies in the baricitinib clinical development have been breast, lung, colorectal, prostate, and renal which are malignancies more frequently observed in the general population. Uncertainties therefore remain as to whether the malignancies observed are reflective of disease morbidity in the target population or a true effect of treatment.

#### Risk factors and risk groups

No specific risk groups or specific risk factors have been identified from the clinical development programme for baricitinib.

### Risk minimisation measures

**[Routine risk minimisation measures:]**

- **SmPC Section 4.4**
- **PIL Section 2**

**[Additional risk minimisation measures:]**

- **PIL Section 2** advises patients to tell their doctor or pharmacist before and during treatment if they have cancer.
### Additional PV activities

Observational post-marketing safety studies to compare the incidence of malignancy in patients exposed to baricitinib with patients exposed to other medications indicated for moderate-to-severe RA:
- National RA registries, such as Corrona
- EU registries
- An observational database study
- Nordic healthcare study

See Section II.C of this summary for an overview of the post-authorisation development plan.

### Important potential risk: Serious and opportunistic infections (including tuberculosis, *Candida* infections, PML)

| Evidence for linking the risk to the medicine | As would be expected from its mode of action, various infections were consistently observed throughout the clinical development programme for baricitinib and, overall, affected approximately one-half of the study population exposed to baricitinib. The evidence was considered sufficient to conclude that some infections (upper respiratory tract infections, herpes zoster, herpes simplex, pneumonia and urinary tract infection) were adverse effects of the product. The profile of infections observed was mainly of a nonserious nature with rates consistent with those observed with other RA therapies.

The evidence source for the request to add PML to this safety concern was on the basis of a single case report with another JAK inhibitor. To date, no cases of PML have been reported with baricitinib. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factors and risk groups</td>
<td>Analysis on the CT data for baricitinib shows that concomitant corticosteroids use, prior biological medicines use, being underweight, overweight, or obese, living in the Asian region, and advanced age (≥ 50 years old) are the key risk factors for serious infections.</td>
</tr>
<tr>
<td>Risk minimisation measures</td>
<td>Routine risk minimisation measures:</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td></td>
<td>SmPC Sections 4.4 and 4.8</td>
</tr>
<tr>
<td></td>
<td>PL Section 2</td>
</tr>
<tr>
<td></td>
<td>SmPC Section 4.4 advises that the risks and benefits of treatment should be considered prior to initiating therapy in patients with active, chronic, or recurrent infections. It also recommends that if an infection develops, the patient should be monitored carefully and Olumiant should be temporarily interrupted for any infection that is not responding to standard therapy. Treatment should not be resumed until the infection resolves.</td>
</tr>
<tr>
<td></td>
<td>• SmPC Section 4.4 advises that patients should be screened to rule out active TB and active viral hepatitis before starting Olumiant.</td>
</tr>
<tr>
<td></td>
<td>• SmPC Section 4.4 advises that live, attenuated vaccines should not be used during, or immediately prior to treatment. It also recommends that, prior to starting treatment, all patients be brought up to date with all immunisations.</td>
</tr>
<tr>
<td></td>
<td>• Section 2 of the PL advises patient that they need to talk to their doctor or pharmacist before and during treatment with Olumiant if they have an infection or if they often get infections. It also advises patients that they should tell their doctor if they get signs of TB, herpes zoster or have, or have previously had, hepatitis B or C.</td>
</tr>
<tr>
<td></td>
<td>Additional risk minimisation measures:</td>
</tr>
<tr>
<td></td>
<td>Healthcare Professional Educational Material</td>
</tr>
<tr>
<td></td>
<td>Patient Alert Card</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Additional PV activities</th>
<th>Additional PV activities:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observational post-marketing safety studies to compare the incidence of serious and opportunistic infections (including tuberculosis, <em>Candida</em>, and PML) in patients exposed to baricitinib with patients exposed to other medications indicated for moderate-to-severe RA:</td>
</tr>
<tr>
<td></td>
<td>National RA registries, such as Corrona</td>
</tr>
<tr>
<td></td>
<td>EU registries</td>
</tr>
<tr>
<td></td>
<td>An observational database study</td>
</tr>
<tr>
<td></td>
<td>Nordic healthcare study</td>
</tr>
<tr>
<td></td>
<td>See Section II.C of this summary for an overview of the post-authorisation development plan.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Important potential risk:</th>
<th>Myelosuppression (agranulocytosis)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence for linking the risk to the medicine</td>
<td>Treatment with baricitinib was associated with decreased neutrophil counts in 11.5% of patients, and this was consistent across CTs. Cases in which the ANC fell transiently to &lt; 500/mm³ (CTCAE Grade 4 neutropenia) were confined to 5 patients (0.14%). Importantly, the observed neutropenia, regardless of the level to which the ANC fell, did not appear to be associated with a higher risk of serious infections. Although “neutropenia &lt;1000 cells/mm³ is an acknowledged adverse effect of baricitinib treatment and listed as such in the SmPC, there is no current evidence to support agranulocytosis (defined as &lt;100 cells/mm³) as an important potential risk independent of the “Serious Infections” already included as a safety concern in the EU RMP, this takes into account that the well-known outcome of low white cell counts is infection.</td>
</tr>
<tr>
<td>Risk factors and risk groups</td>
<td>No risk factors for myelosuppression (agranulocytosis) have been identified. Agranulocytosis during baricitinib treatment either in clinical development or post-marketing has not been observed.</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Risk minimisation measures  | [Routine risk minimisation measures:]  
SmPC Sections 4.2,4.4, 4.8, and 5.3  
PL Sections 2 and 4  
SmPC Sections 4.2 and 4.4 recommend that treatment should not be initiated or should be temporarily interrupted in patients with white cell counts or a haemoglobin that is below a certain level.  
PL Section 2 advises patients that they may need blood tests prior to or during treatment to check if they have a low red or white blood cell counts.  
[Additional risk minimisation measures:] None. |
| Additional PV activities    | Additional PV activities:  
Observational post-marketing safety studies to monitor the incidence of myelosuppression in patients exposed to baricitinib:  
National RA registries, such as Corrona  
EU registries  
An observational database study  
Nordic healthcare study  
See Section II.C of this summary for an overview of the post-authorisation development plan. |
| Important potential risk: Myopathy including rhabdomyolysis | Evidence for linking the risk to the medicine:  
Although increased creatinine phosphokinase >5 x ULN is an uncommon adverse effect of baricitinib listed in the SmPC, the strength of evidence linking the muscle enzyme (CPK) elevations observed during treatment with clinically significant or concerning adverse outcomes such as myopathy or severe muscle damage (rhabdomyolysis) is weak. As described in the prescribing information, treatment with baricitinib was associated with a rapid (within 1 week) increase in CPK values that plateaued after approximately 8 to 12 weeks of treatment. Discontinuation of baricitinib due to an increased CPK or musculoskeletal adverse event symptoms was uncommon (0.4%). In addition, there have been no confirmed cases of rhabdomyolysis from either CT or spontaneous sources. |
| Risk factors and risk groups | As the incidence rate of muscle symptoms in CT development has been so low and no confirmed cases of rhabdomyolysis have been reported, it is not possible to identify any specific patient risk factors for these conditions. |
| Risk minimisation measures  | [Routine risk minimisation measures:]  
SmPC Section 4.8 (increases in CPK)  
PL Section 4 (increases in CPK)  
[Additional risk minimisation measures:] None. |
| **Additional PV activities** | **Additional PV activities:**  
Observational post-marketing safety studies to monitor the incidence of myopathy including rhabdomyolysis in patients exposed to baricitinib: 
National RA registries, such as Corrona 
EU registries 
An observational database study 
Nordic healthcare study 
See Section II.C of this summary for an overview of the post-authorisation development plan. |
|-------------------------------|-------------------------------------------------------------------------------------------------
| **Important potential risk:** Potential for drug-induced liver injury | **Evidence for linking the risk to the medicine**  
Increases in the liver enzymes ALT and AST to $\geq 5$ and $\geq 10 \times$ ULN were reported in 1.2% and 0.3% of patients, respectively, of patients in CTs, and these increases are considered to be adverse effects of baricitinib. None of these enzyme changes were linked to clinically significant evidence of DILI and only 0.2% of adverse events for hepatic disorders were considered by the investigators to be serious. Post-marketing, there have been few reports describing the increased liver enzymes typically seen in the CT programme, but none have involved evidence of actual liver injury. |
| **Risk factors and risk groups** | No risk groups or specific risk factors have been identified from the clinical development programme, although concurrent use of baricitinib with potentially hepatotoxic medicinal products, such as methotrexate, results in a higher frequency of liver enzyme elevations. |
| **Risk minimisation measures** | **[Routine risk minimisation measures:]*  
SmPC Sections 4.2, 4.4, and 4.8  
PIL Sections 2 and 4  
SmPC Section 4.2 recommends that Olumiant should not be used in patients with severe hepatic impairment.  
Section 4.4 recommends that if increases in ALT or AST are observed and DILI is suspected, Olumiant should be interrupted.  
• Section 2 of the PL advises patients to speak to their doctor if they have, or have previously had, hepatitis B or C or if they have poor liver function.  
[Additional risk minimisation measures:] None. |
| **Additional PV activities** | **Additional PV activities:**  
Observational post-marketing safety studies to monitor the incidence of DILI in patients exposed to baricitinib: 
National RA registries, such as Corrona 
EU registries 
An observational database study 
Nordic healthcare study 
See Section II.C of this summary for an overview of the post-authorisation development plan. |
| **Important potential risk:** Gastrointestinal perforation |
### Evidence for linking the risk to the medicine

Although there is a pharmacologically plausible basis for an association between baricitinib and GI perforation, there are insufficient data to establish it as an adverse effect of treatment at this time. The frequency of cases indicative of GI perforation is very low in CTs (less than 0.1 % of patients), and in each case there have been significant confounding factors such as use of steroids and GI surgery. The overall incidence of GI perforations was 0.04 events per 100 PY) and this is within the published rates reported in patients with rheumatoid arthritis (0.02-0.39 per 100 PY).

Patients with RA may be at an increased risk of GI perforation because of prescribed medication and/or because of the consequences of the disease process itself (e.g., vasculitis). As a result, the determination of whether or not the limited observations reflect underlying disease morbidity as opposed to an adverse effect of baricitinib is challenging and will be systematically monitored in the proposed registries in the PV plan for the product.

### Risk factors and risk groups

No specific risk factors for GI perforation have been identified with baricitinib.

### Risk minimisation measures

[No risk minimisation measures]

### Additional PV activities

Additional PV activities:
- Observational post-marketing safety studies to monitor the incidence of GI perforation in patients exposed to baricitinib:
- National RA registries, such as Corrona
- EU registries
- An observational database study
- Nordic healthcare study

See Section II.C of this summary for an overview of the post-authorisation development plan.

### Important potential risk

Major adverse cardiovascular events as an outcome of hyperlipidaemia
### Evidence for linking the risk to the medicine

Consistent with a pharmacologic effect of JAK inhibition, dose-dependent increases in blood lipid levels (including total cholesterol, triglycerides, LDL-C, and HDL-C) were observed throughout the clinical development programme for baricitinib. The increase in LDL-C and all parameters occurred within the first 12 weeks of treatment and remained stable thereafter.

The overall evidence was considered sufficient to conclude that hypercholesterolaemia was an adverse effect of the product. Long-term exposure to increases in blood lipids in the general population would be expected to be associated with adverse CV outcomes (MACE), but literature sources indicate that they may not be harmful to RA patients as the benefits of suppression of inflammation may outweigh the risk of the lipid changes. In this regard, few MACEs were observed in clinical development, and no relationship was observed between MACE and LDL-C increases. As noted in the original submission, the increases in LDL-C observed with baricitinib treatment are responsive to statin treatment, and no direct link to major adverse CV outcomes has been established to date.

Rheumatoid arthritis is however, a chronic condition and one in which patients are already at higher risk of CVD. As such, patients treated with baricitinib in usual clinical practice may be treated for several years and in higher numbers than exposed in CTs. As the long-term effects of these lipid changes on adverse CV outcomes in these circumstances are uncertain, MACE has been classified as an important potential risk warranting further systematic study in the PV Plan of this RMP.

### Risk factors and risk groups

No specific risk factors for hyperlipidaemia have been identified with baricitinib. Similarly, the number of patients in whom MACE has been reported in CTs remains very low. As a result, no specific risk factors for MACE have been identified with baricitinib.

Based on CT data, compared to the patients without MACE, patients with MACE were more likely to have the following CV risk factors at baseline: older age, longer RA disease duration, cigarette smoking, prior cardiac disorder, hypertension, obesity, and hypercholesterolaemia. However, the risk factors for MACE observed in this CT population are typical of risk factors for MACE in the general population. The extent to which prevalence of CVD in patients with RA is a contributory factor is unknown.

### Risk minimisation measures

**[Routine risk minimisation measures:]**

SmPC Sections 4.4 and 4.8 (hypercholesterolaemia and hypertriglyceridaemia)

PIL Section 2

SmPC Section 4.4 advises that lipid parameters should be assessed at 12 weeks following treatment initiation and thereafter according to international guidelines.

PL Section 2 advises patients that they may need blood tests while taking Olumiant to check if they have a high cholesterol level

**[Additional risk minimisation measures:]**

Healthcare Professional Educational Material (lipid monitoring)

Patient Alert Card
### Additional PV activities

Additional PV activities:
- Observational post-marketing safety studies to monitor the incidence of MACE as an outcome of hyperlipidaemia in patients exposed to baricitinib:
  - National RA registries, such as Corrona
  - EU registries
  - An observational database study
  - Nordic healthcare study

See Section II.C of this summary for an overview of the post-authorisation development plan.

### Important potential risk: Foetal malformation following exposure in utero

| Evidence for linking the risk to the medicine | Studies in rats and rabbits dosed in excess of the maximum human exposure, have shown reproductive toxicity when baricitinib was dosed during the early stages of pregnancy. These animal studies indicate that baricitinib may have an adverse effect on bone development in utero at these higher dosages. There is no current evidence of similar findings in the babies of mothers who have been treated with baricitinib during pregnancy but experience at this time is very limited. As a result, the effects of baricitinib on the bone development of the baby prior to birth are unknown and, as advised in the prescribing information, women of childbearing potential should not become pregnant when treated with baricitinib. |
| Risk factors and risk groups | No risk factors have been identified as there are currently no data from CTs or post-marketing data sources in human pregnancy indicative of the bone effects observed in the nonclinical studies. The highest risk period is considered to be the first 12 weeks of pregnancy; however, pregnant or lactating women were excluded from CTs with baricitinib, and experience in human pregnancy is limited. Therefore, neither specific duration of treatment nor risk period have been identified. |
| Risk minimisation measures | [Routine risk minimisation measures:]  
|---------------------------|--------------------------------------|  
| SmPC Sections 4.3, 4.6, and 5.3  
| PIL Section 2  
| SmPC Sections 4.3 and 4.6 state that pregnancy is a contraindication.  
| SmPC Section 4.6 advises that patients of childbearing potential should use effective method of contraception to avoid becoming pregnant during treatment and for at least 1 week after the last treatment.  
| Section 4.6 of the SmPC also advises that a decision must be made whether to discontinue breastfeeding or to discontinue Olumiant therapy.  
| PL Section 2  
| States that patients should not take Olumiant if they are pregnant or think that they may be pregnant  
| Advises patients that if they are pregnant, think they may be pregnant, or are planning to have a baby, they should ask their doctor or pharmacist for advice before taking the medicine  
| States that patients should use an effective method of contraception to avoid becoming pregnant during treatment and for at least 1 week after the last Olumiant treatment  
| States that patients must tell their doctor if they become pregnant.  
| [Additional risk minimisation measures:]  
| Healthcare Professional Educational Material (lipid monitoring)  
| Patient Alert Card  
| Additional PV activities | Additional PV activities:  
| Observational post-marketing safety studies to monitor the incidence of foetal malformation following exposure in utero in patients exposed to baricitinib:  
| Nordic healthcare study  
| See Section II.C of this summary for an overview of the post-authorisation development plan.  
| Important potential risk: Venous thromboembolic events | There is currently insufficient evidence that VTE is an adverse drug reaction of baricitinib treatment. However, a numerical imbalance in reports of DVT and PE during the 16-week placebo-controlled portion of the baricitinib CTs was noted in clinical development (5 cases versus 0). This imbalance formed the basis for VTE being classified as an important potential risk. When assessing this imbalance, it was noted that there was no consistency across studies (VTE was only reported in 2 of the 8 completed RA studies), there was no dose response, no association was observed with any of the observed platelet counts, and all patients who developed a VTE had recognised risk factors.  
| Risk factors and risk groups | All patients who developed VTE had recognised and well-established risk factors for thromboembolism, namely older age, obesity, nonsteroidal anti-inflammatory drug use, and medical history of DVT and PE |
### Risk minimisation measures

**[Routine risk minimisation measures:]
SmPC Section 4.4**

**PIL Section 2**

SmPC Section 4.4 advises that:
Olumiant should be used with caution in patients with risk factors for VTE and that if clinical features of VTE occur, treatment should be temporarily interrupted and patients should be evaluated promptly and appropriately treated.

PL Section 2 advises patients:
To talk to their doctor or pharmacist before and during treatment if they have previously had a VTE or if they develop symptoms of VTE.

That Olumiant should be used with caution in patients with risk factors for VTE.
That treatment should be temporarily interrupted if clinical symptoms of VTE occur.

**[Additional risk minimisation measures:]
None.**

### Additional PV activities

Additional PV activities:

Observational post-marketing safety studies to monitor the incidence of VTE in patients exposed to baricitinib:
National RA registries, such as Corrona
EU registries
An observational database study
Nordic healthcare study
See Section II.C of this summary for an overview of the post-authorisation development plan.

### Important missing information:

**Long-term safety**

<table>
<thead>
<tr>
<th>Risk minimisation measures</th>
</tr>
</thead>
</table>
| [Routine risk minimisation measures:]
SmPC Sections 4.4 and 4.8 (hypercholesterolaemia and hypertriglyceridaemia) |
| PL Sections 2 and 4 |
| No additional recommendations are included in the SmPC or PL other than those already stated for malignancy and MACE. |

<table>
<thead>
<tr>
<th>Additional PV activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional PV activities:</td>
</tr>
<tr>
<td>Observational post-marketing safety studies to monitor long-term safety in patients exposed to baricitinib:</td>
</tr>
<tr>
<td>National RA registries, such as Corrona</td>
</tr>
<tr>
<td>EU registries</td>
</tr>
<tr>
<td>An observational database study</td>
</tr>
<tr>
<td>Nordic healthcare study</td>
</tr>
<tr>
<td>See Section II.C of this summary for an overview of the post-authorisation development plan.</td>
</tr>
</tbody>
</table>

**Important missing information:** Use in very elderly (≥75 years)
| Risk minimisation measures | Routine risk minimisation measures:  
SmPC Sections 4.2, 4.4 (lymphocytosis), and 5.2  
PL Section 3  
SmPC Section 4.2 recommends that in patients ≥75 years, a starting dose of 2 mg is appropriate.  
| Additional risk minimisation measures:  
None. |

| Additional PV activities | Observational post-marketing safety studies to monitor the incidence of use in very elderly (≥75 years) in patients exposed to baricitinib:  
National RA registry, such as Corrona  
An observational database study  
Nordic healthcare study  
See Section II.C of this summary for an overview of the post-authorisation development plan. |

| Important missing information: Use in patients with evidence of hepatitis B or hepatitis C infection | Routine risk minimisation measures:  
SmPC Section 4.4  
PL Section 2  
SmPC Section 4.4 recommends that screening for viral hepatitis should be performed before starting treatment and that if the test is positive, a liver specialist should be consulted.  
Section 2 of the PL advises patients to speak to their doctor if they have, or have previously had, hepatitis B or C.  
| Additional risk minimisation measures:  
None |

| Important missing information: Use in patients with a history of or current lymphoproliferative disease | Routine risk minimisation measures:  
SmPC Section 4.4  
PL Section 2  
PL Section 2 advises patients to tell their doctor or pharmacist before and during treatment if they have cancer.  
| Additional risk minimisation measures:  
None |

| Important missing information: Use in patients with active or recent primary or recurrent malignant disease | Routine risk minimisation measures:  
PIL Section 2  
PL Section 2 advises patients to tell their doctor or pharmacist before and during treatment if they have cancer.  
| Additional risk minimisation measures:  
None |

| Important missing information: Use in paediatric patients |  

II.C. Post-authorisation Development Plan

II.C.1. Studies that Are Conditions of the Marketing Authorisation

There are no studies that are conditions of the marketing authorisation or specific obligation of Olumiant.

II.C.2. Other Studies in Post-authorisation Development Plan

Study short name: Study I4V-MC-B003; Prospective Observational US Postmarketing Safety Registry (Corrona)

Purpose of the study: The rationale for this study is to provide prospective, long-term monitoring in the US of the safety concerns listed in the RMP for baricitinib. There are 2 primary objectives. First, RA patients with long-term exposure to baricitinib will be compared to patients exposed to other medications indicated for moderate-to-severe RA for incidence rates and profiles of various infections, major CV outcomes, malignancies, and venous thrombosis. Second, the study will describe the incidence rates of lymphoma; HZ; opportunistic infections; GI perforation; and serious disorders of the muscle (rhabdomyolysis), bone marrow, blood lipids, white blood cell count, and liver.

A secondary objective of the study is to describe the incidence of the same outcomes in patients who are older than 75 years.

Study short name: Study I4V-MC-B004; Retrospective Cohort Study to Assess Long-Term Safety of Baricitinib

Purpose of the study: The rationale for conducting this study is to characterise the long-term safety of baricitinib in the US using a retrospective study design. Specifically, the study objectives are to monitor the incidence rates and profiles for the safety concerns listed in the RMP, including: various infections, major CV outcomes, malignancies, and venous thrombosis. The incidence rates for these events among patients with long-term exposure to baricitinib will be compared to patients with long-term exposure to other medications indicated for moderate-to-severe RA. Additionally, this study aims to describe the occurrence of lymphoma; HZ; opportunistic infections; GI perforations; and serious disorders of the muscle (rhabdomyolysis), bone marrow, blood lipids, white blood cell count, and liver.
A secondary objective is to describe the incidence of the above outcomes in very elderly patients (aged ≥75 years old).

**Study short name:** Study I4V-MC-B011; Retrospective Cohort Study to Assess Safety of Baricitinib in Nordic countries

**Purpose of the study:** The rationale for conducting this study is to characterise the long-term safety of baricitinib among RA patients treated in routine clinical care in Nordic countries using a retrospective study design.

Specifically, the objectives include 1) to compare the incidence rates and profiles of: serious and opportunistic infections, MACE, malignancies, and VTE in RA patients with long-term exposure to baricitinib, which will be compared to similar patients with long-term exposure to other indicated medications; and 2) to describe the occurrence of lymphoma; HZ; opportunistic and fungal infections; GI perforations; and serious disorders of the muscle, bone marrow, blood lipids, white blood cell count, and liver.

A secondary objective is to monitor the incidence of the major outcomes among patients aged 75 years or older. Another secondary objective is to assess the effectiveness of risk minimisation activities by describing the pattern of use of baricitinib and the occurrence of pregnancy, active TB, or active viral hepatitis and the monitoring of lipid levels in relation to baricitinib use in routine clinical care.

**Study short name:** Study I4V-MC-B012; Observational post marketing surveillance in 3 EU registries

**Purpose of the study:** The rationale for this study is to provide prospective, long-term safety monitoring for baricitinib in routine clinical practice in the EU.

The study objectives are to monitor the incidence rate and profile of various serious and opportunistic infections, MACE, malignancies, and VTE in EU RA patients with long-term exposure to baricitinib. This information will be compared to patients with long-term exposure to other medications indicated for moderate-to-severe RA. A second objective will aim to describe the occurrence of lymphoma; HZ; opportunistic infections; GI perforations; and serious disorders of the muscle, bone marrow, white blood cell count, and liver.

---

**Major Changes to the Risk Management Plan over Time**

- **June 2017:** VTE added as an important potential risk.
- **June 2017:** In vitro study to investigate the inhibitory effect of baricitinib on OAT2 completed.
- **September 2017:** Vaccine study completed.
- **March 2020:** EU PAS Study I4V-MC-B010 completed.

---

This summary was last updated in 04-2020